Company news

Neurotrope Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals

December 1, 2020

Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

November 19, 2020

Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease

October 5, 2020

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

September 29, 2020

Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease

July 29, 2020

Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia

June 9, 2020

Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease

May 27, 2020

Neurotrope Announces Investor Update Conference Call

May 25, 2020

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

May 17, 2020

Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial

January 21, 2020

Neurotrope, Inc. Announces $18 Million Registered Direct Offering

January 21, 2020

Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value

October 7, 2019

Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease

September 8, 2019

Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy

August 12, 2019

Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results

August 4, 2019

Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team

July 16, 2019

Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease

July 14, 2019

Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented

July 10, 2019

Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019

May 29, 2019

Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel

April 18, 2019

Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer

March 31, 2019

Decks